Outcomes of a cross-sectional ultrasound- based study of cystic fibrosis related liver disease: A real world experience

RECOMMENDED

Pulmonary Fibrosis

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Cyst Fibros

Bonnel AS, Bihouée T, Ribault M, Driessen M, Grèvent D, Foissac F, Truong NH, Benhamida M, Arnouat B, Borghese R, Chedevergne F, Couderc-Kohen L, da Silva J, Grenet D, Houdouin V, Le A, Marchal S, Deneuville E, Pouradier D, Rousseau V, Treluyer JM, Francart A, Steffann J, Reix P, Benaboud S, Mamzer MF, Ville Y, Martin C, Burgel PR, Sermet-Gaudelus I, MODUL-CF study group

doi: 10.1016/j.jcf.2025.03.009

RECOMMENDED

Pulmonary Fibrosis

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group

doi: 10.1016/S2213-2600(24)00208-X

RECOMMENDED

Pulmonary Fibrosis

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data

★ 1 Recommended by Dr Martin Frey, Faculty Member

Sci Rep

Imrei M, Kéri AF, Gács É, Gönczi I, Meláth M, Kosaras É, Demeter B, Péterfia C, Vass K, Székely G, Ocskay K, Párniczky A

doi: 10.1038/s41598-025-86010-1

Pulmonary Fibrosis

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

J Cyst Fibros

Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB

doi: 10.1016/j.jcf.2025.04.012

Pulmonary Fibrosis

Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes

Respir Med

Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V

doi: 10.1016/j.rmed.2025.108221

RECOMMENDED

COPD

Tracking Real-World Physical Activity in Chronic Obstructive Pulmonary Disease Over One Year: Results from a Monocentric, Prospective, Observational Cohort Study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Int J Chron Obstruct Pulmon Dis

Boesch M, Baty F, Bilz S, Brutsche MH, Rassouli F

doi: 10.2147/COPD.S469984

RECOMMENDED

Pulmonary Fibrosis

BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis

★ 1 Recommended by Dr Martin Frey, Faculty Member

Respir Med

Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T

doi: 10.1016/j.rmed.2025.108080

RECOMMENDED

COPD

Associations of comorbid heart disease and depression/anxiety with multidimensional breathlessness in COPD - a cross-sectional study

★ 1 Recommended by Dr Martin Frey, Faculty Member

Respir Med

Eliason G, Ekström M, Montgomery S, Giezeman M, Hasselgren M, Janson C, Kisiel MA, Lisspers K, Nager A, Sandelowsky H, Ställberg B, Sundh J

doi: 10.1016/j.rmed.2025.108053

RECOMMENDED

Pulmonary FibrosisPneumonia

Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Dhochak N, Lodha R, Jat KR, Iqbal J, Kumar P, Goyal JP, Varkki S, Kabra SK, CF study group in alphabetical order with equal contribution

doi: 10.1016/j.rmed.2025.108087

Related content

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes

Tracking Real-World Physical Activity in Chronic Obstructive Pulmonary Disease Over One Year: Results from a Monocentric, Prospective, Observational Cohort Study

BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis

Associations of comorbid heart disease and depression/anxiety with multidimensional breathlessness in COPD - a cross-sectional study

Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study